Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-cell vaccination in multiple sclerosis.

Anat Achiron1, Mathilda Mandel

  • 1Center for Multiple Sclerosis, Sheba Medical Center, Tel-Hashomer 52621, Israel. achiron@post.tau.ac.il

Autoimmunity Reviews
|February 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Neurodegenerative disease management·2026
Same author

Digital Color Vision Testing Reveals Widespread Cone Dysfunction in Multiple Sclerosis Independent of Optic Neuritis.

European neurology·2025
Same author

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Therapeutic advances in neurological disorders·2025
Same author

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study.

Neurology and therapy·2025
Same author

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

Frontiers in immunology·2025
Same author

Development of an interactive biosensing application for assessing finger dexterity.

Digital health·2025

T cell vaccination (TCV) targets autoreactive T cells in multiple sclerosis (MS). Studies show TCV is safe and effective, reducing relapses and disability progression in MS patients.

Area of Science:

  • Neuroimmunology
  • Autoimmunity
  • Vaccinology

Background:

  • Autoreactive T cells against myelin antigens are central to multiple sclerosis (MS) pathogenesis.
  • T cell vaccination (TCV) is a therapeutic strategy designed to induce an immune response against these pathogenic T cells.

Purpose of the Study:

  • To evaluate the safety and efficacy of T cell vaccination (TCV) in patients with multiple sclerosis (MS).
  • To investigate the potential of early TCV intervention to prevent epitope spreading in MS.

Main Methods:

  • Immunization protocols were applied in animal models (experimental autoimmune encephalomyelitis) and MS patients.
  • Clinical trials assessed TCV's impact on T cell populations reactive to myelin peptides.
  • Safety and efficacy were evaluated through clinical outcomes, including relapse rates, disability progression, and MRI lesion load.

Related Experiment Videos

Main Results:

  • Immunization led to the depletion of T cells specific for immunodominant myelin peptides in both animal models and MS patients.
  • Clinical trials demonstrated the safety and efficacy of TCV in a cohort of MS patients.
  • TCV treatment correlated with reduced relapse rates, slowed neurological disability progression, and decreased MRI brain lesion load.

Conclusions:

  • T cell vaccination (TCV) represents a safe and effective therapeutic approach for multiple sclerosis (MS).
  • TCV demonstrates potential in mitigating disease activity and progression in MS.
  • Further investigation, including double-blind, placebo-controlled studies, is warranted to confirm the role of early TCV in preventing disease progression and epitope spreading.